Lynda Charters

A minimum of 5,000 patients with up to 5 years of follow-up will be included in the study, with patients from a variety of practice settings and clinician experiences in 28 countries and 500 sites

Early-onset drusen maculopathy (EODM), is part of the age-related macular degeneration (AMD) phenotype that occurs in individuals under 55 years of age.

Multimodal technology bridges the gap between advanced age-related macular degeneration (AMD) biomarkers and clinical features.

A new study out of Guangzhou, China found that individuals younger than 18 years of age and experiencing high myopia are at a high risk of progressively worsening myopic maculopathy.

Ophthalmologist shares pearls from recent roundtable discussion on topic.

While the potential for fundus images is recognized, the methodology and clinical application must be improved.

A recent study found that despite worldwide reports of ocular inflammatory events being reported after patients received COVID-19 vaccinations, a low amount has been reported in the UK.

Genetic testing is proving to be an evolving technology for ophthalmologists.

Authors believe that PVI and PHMB are not associated with postoperative ocular irritation.

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.

Consensus, awareness, and a CVI registry: top priorities of the trans-NIH event

Patients are encouraged to choose the optimal technology for their particular situation.

A collaborative study between the Max Planck Institute of Psychiatry and the University of California, Irvine, explores the potential of pupillometry as a clinical test for identifying a specific subgroup of patients with major depressive disorder (MDD) characterized by anticipatory hypo-arousal related to anhedonia.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

The Annual Gala will be held on February 8 from 6 to 9 pm Pacific Standard Time.

Patient selection is important.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.

GreenMan app provides patients an opportunity to test drive various IOL options before cataract surgery via virtual and augmented reality.

The first step in management is increasing the time spent outside

The goal is to understand how individuals with CVI interact with their visual world

Vascular compromise is the most ominous early adverse event that can occur when a filler is unintentionally injected into a blood vessel.

Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.

Sharing, learning, networking, collaborating

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.